SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major trending topic as its Q4 earnings, which beat expectations, were met with a significant stock dip, fueling intense debate among investors. The community is sharply divided, with many viewing the sharp decline as a prime 'buy the dip' opportunity for a long-term hold, citing strong fundamentals. Conversely, bears are expressing concerns over cautious guidance, the implications of its Warner Bros. Discovery acquisition, increased content spending, and the pausing of share buybacks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as escalating geopolitical tensions, including President Trump's tariff threats against European nations over Greenland, and growing concerns about US dollar stability drive investors to seek safe havens. The community is actively discussing gold's role as a premier hard asset amidst broad market uncertainty, anticipating further appreciation as capital potentially rotates from equities and traditional bonds.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is a hot topic as the community anticipates significant announcements, fueled by recent industry awards and confirmation of continued work with Celestial AI, now part of Marvell. Discussion centers on POET's patented optical interposer technology, seen as a crucial solution for the escalating demand for high-speed, power-efficient optical interconnects in AI data centers. Many believe the company is poised for major customer orders, positioning it as a key player in the ongoing optical supercycle.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is experiencing a highly polarized trend following a rapid price surge, sparking intense community debate. While many celebrate substantial gains and anticipate further rallies, a vocal segment warns of a potential "rug pull" or pump-and-dump, cautioning investors due to its meme coin characteristics. Amidst this volatility, new participants are actively seeking information on how to acquire the token.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is trending due to renewed tariff threats from a US political figure concerning an international territory, fueling global trade war fears. This has sparked widespread community discussion, with many anticipating significant market volatility and potential capital flight, while others remain optimistic about a swift market rebound amid broader geopolitical tensions.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst escalating geopolitical trade tensions and recent service outages, which have contributed to a broader tech sell-off and driven its daily RSI to historically oversold levels. The community is sharply divided between those advocating to "buy the dip" ahead of anticipated strong earnings and others who question its long-term growth trajectory under current market pressures.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust (SPY) is actively trending amid heightened geopolitical rhetoric, particularly surrounding discussions of a potential U.S. acquisition of Greenland and associated tariff implications. The community is sharply divided, with many anticipating a significant rebound from a recent market dip, while others express concerns about escalating global tensions and upcoming public statements from a prominent political figure. Broader market sentiment is currently influenced by a tug-of-war between 'buy the dip' enthusiasm and fears of further instability affecting international asset holdings.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation is trending due to its recent listing on Kraken and increased accessibility via the Base network, alongside new partnerships including a Web3 National Lottery integration in the Philippines. The community is keenly focused on Constellation's strategic shift towards enterprise and government use cases, like its long-standing DoD contracts and recent MiCAR compliance, highlighting its Layer 0 Hypergraph architecture for secure data solutions in the AI era.

CACI International, Inc. is a holding company, which engages in the provision of information solutions and services in support of national security missions and government transformation for intelligence, defense, and federal civilian customers. It operates through the Domestic Operations and International Operations segments. The Domestic Operations segment offers information solutions and services to U.S. federal government agencies, state and local governments, and commercial enterprises to different market areas, including business systems, command and control, communications, cyber security, enterprise information technology, health, intelligence services, investigation and litigation support, logistics and material readiness, and surveillance and reconnaissance. The International Operations segment includes the provision of IT services and proprietary data and software products, serving commercial and government customers. The company was founded by Herb Karr and Harry Markowitz in July 1962 and is headquartered in Reston, VA.

Caci International Inc. - Registered Shares - Class A

CACI International is trending following recent strategic acquisitions and significant contract wins across critical national security, space, and defense technology sectors, further bolstered by a substantial share repurchase program. The community is notably bullish, highlighting the company's robust position in government-mandated areas like AI and cybersecurity, often seen as a resilient investment despite broader defense spending discussions.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending sharply following Kimberly-Clark's proposed acquisition, which offers a notable premium over recent trading levels and is sparking significant merger arbitrage interest. This comes amidst ongoing legal complexities, including persistent talc liabilities from its former parent and highly scrutinized Tylenol-autism claims, which continue to fuel community debate on the stock's fundamental value versus its litigation risks. Investors are actively weighing the long-term potential of Kenvue's iconic consumer health brands against these prominent legal overhangs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.</li><li>BRIUMVI’s U.S. net product revenue expected to reach around $182 million in Q4 and $594 million in 2025.&nbsp;</li><li>TG Therapeutics stock rallies 9% higher in Wednesday’s premarket.&nbsp;</li></ul>TG Therapeutics, Inc. (TGTX) drew increased attention on Wednesday, with the stock seeing a 195% increase in retail chatter on Stocktwits over the last 24 hours following the company’s ambitious revenue outlook.&nbsp;On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.<h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><a href="https://stocktwits.com/symbol/TGTX">TG Therapeutics stock</a> traded over 9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_083034_png_390ef2e760.webp" alt="TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits" width="933" height="108"><figcaption>TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic about BRIUMVI achieving blockbuster status.<stembedurl>https://stocktwits.com/knowthyself/message/641747123</stembedurl>Another bullish user said the company’s ramp-up from Q3 to Q4 was impressive.&nbsp;<stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/641752748</stembedurl><h2 class="st-heading-2">Outlook Highlights&nbsp;</h2>TG Therapeutics expects BRIUMVI’s U.S. net product revenue to reach around $182 million in Q4 and $594 million for the full year of 2025. Global revenue for the year is estimated at $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.&nbsp;Looking ahead, the company anticipates total global revenue between $875 million and $900 million for 2026, with U.S. BRIUMVI sales projected at $825 million to $850 million.BRIUMVI is a glycoengineered monoclonal antibody that targets CD20-expressing B-cells, a proven approach for treating autoimmune diseases like relapsing multiple sclerosis (RMS). By removing specific sugar molecules, BRIUMVI enhances B-cell depletion at lower doses.<h2 class="st-heading-2">Upcoming Clinical Milestones</h2>The company also teased three major milestones for 2026.&nbsp;TG Therapeutics plans to release pivotal topline data for the ENHANCE trial, which evaluates Day 1 and Day 15 intravenous doses of BRIUMVI, by mid-2026. Preliminary Phase 1 data for azer-cel in Progressive multiple sclerosis (MS) will be shared in the latter half of the year.&nbsp;Pivotal topline results for subcutaneous BRIUMVI are expected by year-end 2026 or early 2027.&nbsp;TGTX stock has declined by over 6% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Biology lab technician removes a freeze-dried sample from a container in a laboratory.

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

Equity

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.


<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;<blockquote>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”-Scott Hutton, CEO, Biodesix</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;BDSX stock declined by over 77% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

<ul class="summary-bullets"><li>Tempus’ 2025 Total Contract Value (TCV) exceeded $1.1 billion.</li><li>The 2025 agreement roster includes global pharma companies such as AstraZeneca, GlaxoSmithKline, and Pfizer.</li><li>Revenue from data and software-based offerings is expected to be approximately $316 million for 2025.</li></ul>Tempus AI, Inc. (TEM) stock gained over 11% in Monday’s premarket after the company reported that its Total Contract Value (TCV) surpassed $1.1 billion by the end of December 2025.Tempus uses artificial intelligence to work with large and diverse sets of medical data and provides tools that help doctors make more personalized treatment decisions.<h2 class="st-heading-2">Record Contract Growth</h2>Tempus secured data and analytics agreements with more than 70 organizations in the last year, showing the broad adoption of its multimodal data platform.&nbsp;The 2025 agreement roster spans global pharmas such as AstraZeneca, GlaxoSmithKline, Pfizer, Novartis, and Merck alongside biotech partners like Incyte and Whitehawk Therapeutics.&nbsp;<blockquote>“Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond.”-Jim Rogers, CFO, Tempus</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/TEM">Tempus AI stock</a> moved to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Retention And Revenue Strength</h2>Tempus also reported strong client retention, with net revenue retention around 126% as existing users increased their commitments in 2025.&nbsp;The company also released its outlook for both the fourth quarter (Q4) and the full year of 2025. For the year ending Dec. 31, 2025, Tempus expects total revenue to reach roughly $1.27 billion, a whopping 83% year-over-year increase. The company sees diagnostic testing as the primary growth engine, generating about $955 million in annual revenue.&nbsp;Revenue from data and software-based offerings is expected to be approximately $316 million for the year. For Q4, Tempus expects revenue to climb to nearly $367 million.&nbsp;TEM stock has gained over 104% in the last 12 months.&nbsp;Also See:<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slips-as-amazon-turns-up-heat-on-weight-loss-drugs/cmU9u36R43M"> Why Is HIMS Stock Slipping Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tempus AI logo is seen displayed on a smartphone screen.

Why Is Tempus AI Stock Surging 11% Premarket Today? 

Tempus secured data and analytics agreements with more than 70 organizations in 2025, showing the broad adoption of its multimodal data platform. 

<ul class="summary-bullets"><li>Tilray’s Q2 revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data</li><li>The management reaffirmed its fiscal 2026 adjusted EBITDA outlook of $62 million to $72 million.</li><li>Tilray is currently operating at an annualized run rate of about $150 million, CEO Irwin D. Simon told analysts on a call on Thursday.</li></ul>Tilray Brands (TLRY) stock gave up most of its early gains to trade about 2.5% higher on Friday after Alliance Global slashed its price target on the stock, pointing to limited visibility into the company’s long-term sales trajectory and cash flow following its second-quarter (Q2) fiscal 2026 results.Analyst Aaron Grey reduced Tilray’s target price to $10 from $20 while maintaining a ‘Neutral’ rating. He said the quarter came in largely in line at the consolidated level, with “some strengths offsetting some weaknesses,” but the firm stayed on the sidelines, looking for clearer insight into the company’s sales and cash flow outlook.<h2 class="st-heading-2">Q2 Print</h2>Tilray’s second-quarter (Q2) revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data. The revenue increase was driven by a 36% jump in international medical cannabis sales. Net loss narrowed to $43.5 million from $85.3 million a year earlier.Operating cash flow remained negative, though it narrowed to $8.5 million compared to $40.7 million last year. The firm’s management reaffirmed its fiscal 2026 adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) outlook of $62 million to $72 million, citing long-term opportunities tied to U.S. cannabis rescheduling and medical expansion.Chairman and CEO Irwin D. Simon told analysts on a call on Thursday that Tilray is currently operating at an annualized run rate of about $150 million, driven mainly by international markets. Simon also added that Europe, particularly Germany, the U.K., and Poland, represents a significant growth opportunity.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday gains, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> remained in the ‘bearish’ territory over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/TLRY_jpg_463814541d.webp" alt="TLRY.jpg" width="922" height="96"><figcaption>&nbsp;</figcaption></figure>However, some users were bullish, with one highlighting Tilray’s strong results.<stembedurl>https://stocktwits.com/Mlitton13/message/641317326</stembedurl>The stock has declined 24% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-oklo-stock-surged-premarket-today-meta-deal/cmU2fX3R4dI">OKLO Stock Surged 20% In Premarket Today – What’s The Meta Agreement About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

TLRY Stock In Focus After Alliance Global Halves Price Target

Alliance Global cut TLRY’s target price to $10 from $20, citing limited visibility into the company’s long-term sales trajectory and cash flow.

Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond

After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.

<ul class="summary-bullets"><li>H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating.</li><li>BTIG said the FDA approval ‘clears a significant overhang’ for MoonLake’s clinical program.</li><li>MoonLake plans to submit its biologics license application in the second half of 2026.</li></ul>MoonLake Immunotherapeutics (MLTX) remained on investors’ radar after its shares rose 5% in premarket trading on Friday, following favorable brokerage action tied to positive feedback from the U.S. Food and Drug Administration (FDA) on its treatment for hidradenitis suppurativa, a chronic inflammatory skin condition.<a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending tickers on Stocktwits at the time of writing.BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ and set a $24 price target, citing a recent regulatory update, according to TheFly.<h2 class="st-heading-2">The FDA Feedback</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">confirmed</a> that MoonLake can establish the effectiveness of Sonelokimab (SLK) in hidradenitis suppurativa without additional trials, a development BTIG believes clears a significant overhang for the company’s clinical program and could position SLK for FDA approval.This would be supported by existing data from the VELA-1, VELA-2, and MIRA studies. The company plans to submit its biologics license application in the second half of 2026.H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating. The company’s FDA meeting outcome delineates a path to registration, the firm said.The stock closed 27% higher on Thursday following the FDA feedback.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/MLTX_jpg_6f56883898.webp" alt="MLTX.jpg">One user sees potential conversations regarding mergers and acquisitions following the FDA feedback.<stembedurl>https://stocktwits.com/Atdanaiw/message/641311151</stembedurl>Another user believes MLTX’s value needs to grow further before a probable acquisition.<stembedurl>https://stocktwits.com/Newcar/message/641308484</stembedurl>MoonLake had reportedly turned down a $3 billion acquisition offer from Merck (MRK) in June last year.The stock has been under heavy selling pressure over the past year, declining more than 70%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-slips-pre-market-after-pricing-300-million-public-offer-at-discount/cmU2ghYR4dQ">GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

<ul class="summary-bullets"><li>The FDA feedback indicates the company can establish&nbsp;substantial evidence of effectiveness without conducting additional&nbsp;hidradenitis suppurativa trials.</li><li>The firm remains on track to submit its Biologic License Application for Sonelokimab in the second half of 2026.</li><li>MoonLake will host an Investor Day on February 23 to review FDA feedback from the Type B meeting.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) surged 45% in premarket trading on Thursday after the company said it received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B meeting regarding Sonelokimab (SLK), a drug used to treat hidradenitis suppurativa (HS), a chronic inflammatory skin disorder.The FDA feedback indicates the company can establish substantial evidence of effectiveness (SEE) without conducting additional HS trials, using a Biologic License Application (BLA) supported by data from its existing VELA-1, VELA-2, and MIRA studies.The agency advised including MIRA results to support efficacy and submitting VELA-2 data to inform the safety profile. Based on the official meeting outcome, the company remains on track to submit its BLA for Sonelokimab in the second half of 2026.“The positive outcome of our Type B meeting with the FDA provides the clarity needed to support a pathway to approval for our existing HS program, with no additional clinical trials required. In addition, the fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” said Jorge Santos da Silva, Founder and Chief Executive Officer at MoonLake Immunotherapeutics.<h2 class="st-heading-2">2026 Pipeline</h2>MoonLake will host an Investor Day on Feb. 23, 2026, to review the FDA feedback from the Type B meeting and share new clinical data for SLK across indications, along with updates to its 2026 catalyst outlook.The company also expects a steady flow of clinical readouts over the next year, including Phase 2 data in axial spondyloarthritis and multiple Phase 3 updates in psoriatic arthritis and HS. Key milestones include a Phase 2 axSpA readout in Q1 2026, several Phase 3 readouts by mid-2026, and a planned BLA submission in the second half of 2026.<h2 class="st-heading-2">How Did Stockwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending stocks on the platform at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MLTX_jpg_70c33bd6fe.webp" alt="MLTX.jpg" width="916" height="96"><figcaption>MLTX's Sentiment Meter and Message Volumes at Premarket on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>One user expects the stock to climb to $22 within a few sessions. It is currently trading at $16.2.<stembedurl>https://stocktwits.com/discountcroesus1/message/641193716</stembedurl>The stock has been under heavy selling pressure over the past year, declining nearly 80%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-vnda-stock-falling-premarket/cmUbEA9R4Pn">Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did MLTX Stock Jump 45% In Pre-Market Today?

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

Insiders Bullish on Certain Holdings of VHT

A look at the weighted underlying holdings of the Vanguard Health Care ETF (VHT) shows an impressive 16.2% of holdings on a weighted basis have experienced insider buying within the past six months...

Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China

Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.

Vanguard Group, Inc. - Vanguard Health Care ETF

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$289.36
Prev Close	$289.71
Open	$286.33
Dividend Yield	N/A
50-Day Moving Average	$287.68
Beta	N/A
Avg. Volume	295,097.86
PE Ratio	N/A

52-Week High	$298.61
52-Week Low	$234.11
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

VHT
Vanguard Health Care ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VHT News

VHTVanguard Health Care ETF